Clinical observation of Entecavir and Tibifidine in the treatment of chronic hepatitis B
LIN Yan1 SUN Yi′ning2
1.Department of Medical, the Affiliated Central Hospital of Shenyang Medical College, Liaoning Province, Shenyang 110024, China;
2.Department of Pharmacy, Shenyang No.242 Hospital, Liaoning Province, Shenyang 110034, China
Abstract：Objective To investigate the clinical effect of Entecavir and Tibifidine in the treatment of chronic hepatitis B. Methods Clinical data of 98 patients with chronic hepatitis B admitted to the Affiliated Central Hospital of Shenyang Medical College from March 2014 to March 2017 were analyzed. According to different treatment methods, the patients were divided into two groups, Tibifidine group (49 cases) and Entecavir group (49 cases). Before and after the treatment, the total bilirubin (TBiL), serum protein (ALB), high mobility group protein-1 (HMGB-1), γ interferon (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10) and hepatitis B virus (HBV) DNA loads of two groups were observed, the E antigen (HBeAg) turn rate, HbeAg serological conversion rate, clinical response rates of two groups were observed. Results Before treatment, TBiL, ALB, HMGB-1, IFN-γ, IL-4, IL-10, and HBV DNA load were compared between the two groups, and the differences were not statistically significant (P ＞ 0.05), after treatment, the TBiL, HMGB-1, IL-4, IL-10 and HBV DNA load of patients in the two groups were all lower than those before treatment, the ALB and IFN-γ were higher than those before treatment, the TBiL, HMGB-1, IL-4, IL-10 and HBV DNA load of patients in the Tibifidin group were lower than those in the Entecavir group, and the ALB and IFN-γ were higher than those in the Entecavir group, the differences were statistically significant (P ＜ 0.05). Comparison of HBeAg conversion rate and HBeAg serological conversion rate between the two groups showed no statistically significant difference (P ＞ 0.05), while the clinical response rate of patients in the Tibifidine group was higher than that in the Entecavir group, with statistically significant difference (P ＜ 0.05). Conclusion The clinical response rate of Tibifidine in the treatment of chronic hepatitis B patients was higher than that of Entecavir, which may be related to the regulation of HMGB-1, IFN-γ, IL-4, IL-10 and HBV DNA load.
林彦1 孙一宁2. 恩替卡韦与替比夫定治疗慢性乙型肝炎的临床观察[J]. 中国医药导报, 2019, 16(15): 104-107.
LIN Yan1 SUN Yi′ning2. Clinical observation of Entecavir and Tibifidine in the treatment of chronic hepatitis B. 中国医药导报, 2019, 16(15): 104-107.
[1] 廖金瑶，肖艺，黄晶，等.替比夫定与恩替卡韦对乙型肝炎病毒感染患者的治疗疗效研究[J].中华医院感染学杂志，2018，28（7）：983-986.
[2] 刘洪锋，延学军.恩替卡韦联合肝动脉化疗栓塞治疗乙型肝炎病毒相关性不可切除肝癌患者的疗效观察[J].安徽医药，2018，22（11）：2234-2236.
[3] 司华，贾琦，丁曲顺．恩替卡韦与替比夫定对慢性乙型病毒性肝炎的临床疗效比较研究[J].国际病毒学杂志，2016，21（3）：203-206.
[4] Tsai WL，Chiang PH，Chan HH，et al. Early entecavir treatment for chronic hepatitis B with severe acute exacerbation [J]. Antimicrob Agents Chemother，2014，58（4）：1918-1921.
[5] 丁荣蓉，施光峰，张占卿，等.替诺福韦酯和恩替卡韦对慢性乙型肝炎初治患者疗效的荟萃分析[J].肝脏，2017， 22（5）：400-403.
[6] Papatheodoridis GV，Dalekos GN，Yurdaydin C，et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir [J]. J Hepatol，2015，62（2）：363-370.
[7] 杨友道，杨润，尹丹萍.替诺福韦酯与恩替卡韦治疗慢性乙型肝炎有效性的网状Meta分析[J].中华医院感染学杂志，2018，28（6）：831-836.
[8] Yang SW，Kim GH，Chung JW，et al. Prediction of risk for hepatocellular carcinoma by response of serum α-fetoprotein to entecavir therapy [J]. J Gastroenterol Hepatol，2015， 30（7）：1175-1182.
[9] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2015更新版）[J].中华肝脏病杂志，2015，23（12）：888-905.
[10] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南年版[J].中华肝脏病杂志，2011， 19（1）：13-24.
[11] 林厚雄.替诺福韦与恩替卡韦治疗HBeAg阳性初治慢性乙型肝炎患者的临床疗效[J].山东医药，2016，56（33）：92-94.
[12] Riveiro-Barciela M，Tabernero D，Calleja JL，et al. Effectiveness and safety of entecavir or tenofovir in a Spanish cohort of chronic hepatitis B patients：validation of the page-B score to predict hepatocellular carcinoma [J]. Dig Dis Sci，2017，62（3）：784-793.
[13] 庞婷，邢卉春.HBV感染者耐药基因突变与肝细胞癌的相关性分析[J].临床肝胆病杂志，2017，33（1）：82-86.
[14] 王贺，邢智远，孙风波，等.替诺福韦与恩替卡韦对高病毒载量HBeAg阳性乙型肝炎患者的疗效比较[J].中国临床新医学，2016，9（10）：882-884.
[15] Shi H，Huang M，Lin G，et al. Efficacy comparison of tenofovir and entecavir in HBeAg-positive chronic hepatitis B patients with high HBV DNA [J]. Biomed Res Int，2016，2016（1）：6725073.
[16] 丁宁玲，龚婵聪，路文明，等.替诺福韦酯对恩替卡韦经治失败的慢性乙型肝炎患者的临床疗效及其安全性评价[J].抗感染药学，2017，14（8）：1480-1483.
[17] Pereira CV，Tovo CV，Grossmann TK，et al. Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil [J]. Mem Inst Oswaldo Cruz，2016，111（4）：252-257.
[18] 高红艳，刘娜，李春霞，等.慢性HBV感染者免疫耐受期自然转归相关影响因素的研究进展[J].临床肝胆病杂志，2017，33（8）：1572-1575.
[19] 刘宇，杜漫，王慧雯，等.替比夫定与恩替卡韦对阿德福韦酯相关肾损害的慢性乙型肝炎患者肾功能改善效果比较及其影响因素[J].广西医学，2017，39（4）：440-443.
[20] Sriprayoon T，Mahidol C，Ungtrakul T，et al. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients：a randomized controlled trial [J]. Hepatol Res，2017，47（3）：E161-E168.
[21] 韩峰，周莹.替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者血清eGFR的动态变化[J].中国现代医学杂志，2018，28（13）：100-103.
[22] Park JW，Kwak KM，Kim SE，et al. Comparison of the long-term efficacy between entecavir and tenofovir in treatment-naive chronic hepatitis B patients [J]. BMC Gastroenterol，2017，17（1）：39.
[23] Han Y，Zeng A，Liao H，et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis：a systematic review and meta-analysis [J]. Int Immunopharacol，2017，42（1）：168-175.
2019, Vol. 16 
京公网安备 11010502046598号